Referenced in: none

Automatically associated channels: Kir2.3

Title: JTV-519 Japan Tobacco.

Authors: H F Tse, W F Lam

Journal, date & volume: , 2001 Jul , 2, 936-9

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/11757794

Abstract
Japan Tobacco is developing the mixed action ion channel blocker, JTV-519, which has potential use as an antiarrhythmic [285800]. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998; phase II trials started in the fourth quarter of 1998 for the potential treatment of myocardial infarction [320195]. Studies have shown that JTV-519 has a strong cardioprotective effect against catecholamine-induced myocardial injury and against ischemia/reperfusion injury [316749]. In experimental myofibrillar overcontraction models, it demonstrated greater cardioprotectant effects than propranolol, verapamil and diltiazem [171668].